Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Q4 2025 value amounting to $148.4 million.

  • Enanta Pharmaceuticals' Short-term Investments rose 1214.28% to $148.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was $148.4 million, marking a year-over-year increase of 1214.28%. This contributed to the annual value of $156.6 million for FY2025, which is 2578.16% down from last year.
  • As of Q4 2025, Enanta Pharmaceuticals' Short-term Investments stood at $148.4 million, which was up 1214.28% from $156.6 million recorded in Q3 2025.
  • Enanta Pharmaceuticals' Short-term Investments' 5-year high stood at $298.8 million during Q1 2021, with a 5-year trough of $132.3 million in Q4 2024.
  • Its 5-year average for Short-term Investments is $206.1 million, with a median of $199.8 million in 2022.
  • Data for Enanta Pharmaceuticals' Short-term Investments shows a peak YoY increase of 7294.2% (in 2024) and a maximum YoY decrease of 5547.31% (in 2024) over the last 5 years.
  • Enanta Pharmaceuticals' Short-term Investments (Quarter) stood at $160.0 million in 2021, then increased by 7.67% to $172.2 million in 2022, then skyrocketed by 72.55% to $297.2 million in 2023, then crashed by 55.47% to $132.3 million in 2024, then grew by 12.14% to $148.4 million in 2025.
  • Its Short-term Investments stands at $148.4 million for Q4 2025, versus $156.6 million for Q3 2025 and $159.3 million for Q2 2025.